Non-covalent incorporation of hydrophobic drugs into polymeric systems is a commonly-used strategy for drug delivery because non-covalent interactions minimize modification of the drug molecules whose efficacy is retained upon release. The behaviors of the drug-polymer delivery system in the biological environments it encounters will affect the efficacy of treatment. In this report, we have investigated the interaction between a hydrophobic drug and its encapsulating polymer in model biological environment using a photosensitizer encapsulated in a polymer- 
Introduction
Controlled release systems for drug delivery using nanocarriers have been developed and studied for more than three decades. 1 Au nanostructures have been used as drug delivery vehicles in chemotherapy because of their biocompatibility, facile surface modification, and robust optical properties. [2] [3] [4] [5] [6] [7] [8] While drug molecules can be covalently immobilized on the nanoparticles' surface, 2, [8] [9] [10] non-covalent interactions are particularly appealing because they minimize modification of the drug molecules, whose efficacy is then largely retained upon release. Several strategies have been developed to non-covalently tether molecules through electrostatic and hydrophobic interactions to polymer-coated nanoparticles, which include wrapping into layer-bylayer assembled polyelectrolytes, 11 entrapping in a polymer monolayer, [12] [13] [14] encapsulating into a phospholipid bilayer, 15 and absorbing into a hydrogel. 16 Among these methods, poly(ethylene glycol) (PEG) coated nanoparticles are advantageous because PEG used widely in the pharmaceutical industry is generally nontoxic and possesses antifouling properties well-suited for increasing circulation half-life and minimizing immunological clearance. 17 The graft density of PEG was found to significantly affect the biological fate of the particles. 18 Hydrophobic phthalocyanine photosensitizers [19] [20] [21] or anti-cancer drugs 22, 23 have been delivered within the surface PEG layer or inside the hydrophobic pocket for photodynamic therapy or chemotherapy.
We recently applied a similar system to deliver a hydrophobic porphyrin-derivative (3-(1'-hexyloxyethyl)-3-devinylpyropheophorbide-a, HPPH, structure shown in Fig. 1A ) for imageguided photodynamic therapy with enhanced efficacy. 14 In this work, we systematically investigate the binding affinity and the release kinetics of HPPH from PEG-coated Au nanocages (AuNCs) to further elucidate the behavior of the drugpolymer delivery system. The induced-dipole/induced-dipole interactions between the 4 pheophorbide and the PEG backbone serve as the driving force to load molecules into the PEG layer. 24 HPPH is stably integrated within the PEG coating of AuNC-HPPH in saline solution.
The release itself is mediated by either serum proteins (specifically albumin in our model) or cell membranes (modelled here with vesicles). The serum proteins unloaded the drug over several hours and the release of entrapped molecules can be endogenously controlled by the charge and functionality of the PEG terminus. Additionally, the release rate can be exogenously controlled by utilizing the photothermal (PT) effect of Au nanostructures which allows external and temporal control of the drug release by non-invasive near-infrared light. [25] [26] [27] 11, 28 By manipulating these variables, we are able to demonstrate on-demand unloading of the drug with minimal premature loss and were able to suggest the relative affinity of the drug for soluble proteins versus cell membranes. were acquired after the dilution at various intervals throughout a 32 h period using  ex = 605 nm and  em = 668 nm. Samples were kept at room temperature, in the dark, without stirring or unnecessary agitation between measurements. At the end of the data acquisition, 10 L of 0.5 M aqueous KCN was added to dissolve AuNCs and the fluorescence spectrum was acquired to determine the maximum (100%) HPPH signal for the sample. PBS samples were monitored 6 using supernatant absorbance at various times following centrifugation. After measurement, the pellet was redispersed in the original supernatant.
METHODS

Incorporation of HPPH to
To test the PT effect on the release kinetics, an 808-nm diode laser (Power Technology) was used to irradiate the suspension of AuNC-HPPH complexes. The laser intensity was adjusted to a power density of 1 W/cm 2 by changing the spot size to maintain the temperature at ~46 o C. The fluorescence measurement was taken at different time periods over the course of 2 h irradiation, and irradiation began within 10 s of introduction of sample into BSA. On-demand release was demonstrated using 5 min irradiation pulses followed by 10 min without irradiation.
RESULTS AND DISCUSSION
The AuNC-HPPH complexes were prepared according to our previously-reported method by covalently attaching HS-PEG-X to the nanoparticle surface and subsequently encapsulating HPPH into the PEG coating. 14 AuNCs with an average exterior edge length of 53  8 nm and interior edge length of 41 ± 6 nm measured from TEM were synthesized for this study. After their surface was coated with HS-PEG-NH 3 + , the LSPR of the AuNCs was centered at 801 nm ( Fig. 1B) , slightly red-shifted from the LSPR of the "bare" AuNCs at 798 nm ( Fig. S1A ). This LSPR maximum falls within the tissue transparent window and overlaps the 808 nm wavelength of the diode laser utilized for PT release. Figure 1C shows the spectral changes after loading; the LSPR of AuNCs was further red-shifted to 829 nm, which is attributed to a change in the refractive index of the local surface environment. 29 The peaks at 512, 545, 617, and 669 nm are attributed to absorption by the HPPH molecules ( (Fig. 2B) was developed, and Scatchard analysis results in a plot that is both hyperbolic and concave up, consistent with nonspecific binding between PEG and HPPH. 34 The data were fitted to the equation 
The fluorescent properties of HPPH inside the PEG layer on the AuNCs were examined by fluorescence lifetime measurements (Fig. 3A) . Due to quenching, the quantum yields were very low, but a weak signal was present that was able to be picked up using the microscope setup. The HPPH lifetime (τ avg ) for AuNC-HPPH was measured to be 1.39 ns, comparable to that in PBS (1.51 ns) and appreciably shorter than in methanol (6.55 ns) or BSA (7.21 ns). Even when the loading concentration was reduced to 5 × 10 3 HPPHs per AuNC, the lifetime increased only slightly to 2.69 ns. These data suggest that the HPPH molecules in AuNC-HPPH are in close proximity to each other, similar to the small aggregates that have been generated in PBS. 36 The proximity of HPPH to the AuNC surface was further characterized by Raman spectroscopy ( concentration gave rise to a typical Raman peak at 1590 cm -1 that corresponds to the vibration of aromatic bonds in the macrocycle, 37 suggesting that the pheophorbide ring is oriented somewhat perpendicularly to the surface of the metal. 38 At low concentration, the Raman signature disappeared and was replaced by a broad fluorescence peak centered at 2340 cm -1 . These data suggest that HPPH may be driven deeper in the coating and closer to the metal surface at higher concentrations, highlighting that HPPHs were densely packed within the PEG layer. 5 HPPHs/AuNC, 1 pM AuNC); spectra were acquired over 300 s using 488 nm excitation.
The release of the drug was monitored in a serum-mimetic environment to simulate intravenous injection (Fig. 4A) . 39 Fluorescence gradually recovered over 32 h when incubated in 4 wt % BSA (~600 µM, 37 °C, pH = 7.4). 40 As a control, AuNC-HPPH was also incubated in PBS, and release was monitored using supernatant absorbance at various times compared to the maximum. It was found that 86.3 ± 7.6 % of HPPH had been unloaded in the BSA solution within 24 h, but only 4.7 ± 2.1 % of the payload had unloaded in PBS. PEG monolayers are known to resist formation of a "hard" (nonremovable) protein corona, 41, 42 therefore the release is attributable to the formation of the "soft" protein corona, which entails rapid adsorption and desorption of serum proteins on the PEG surface. 43, 44 Ideally, AuNC-HPPH is anticipated to unload the HPPH in the tumor cell membrane for maximal photodynamic effect due to the short lifetime of singlet oxygen. Vesicles were prepared with a 3:1 mole ratio of DMPC and DMPG to mimic the composition of human cell membranes.
Incorporation of HPPH in the vesicle membrane (1 mM lipid solution) leads to recovery of its fluorescence; therefore the release could be monitored similarly to BSA solutions. The release of HPPH to the vesicle solution was compared for free HPPH and AuNC-HPPH (Fig. 5) . Similar to the BSA solution, ~90 % of the HPPH unloaded from AuNC-HPPH after 24 h. It is worth noting that unlike tumor cells, the vesicles were free in solution and could interact freely with suspended particles, artificially inflating the kinetics of the process. Interestingly, free HPPH did not reach its maximum signal until between 2 and 4 h incubation in the vesicle solution, whereas the BSA solution of free HPPH reached a maximum within 10 min. These results imply that kinetics of HPPH adsorption is much more rapid for BSA than for the cell membrane. However, the ultimate release amount of HPPH from AuNC-HPPH is comparable for both systems, which suggests that diffusion is a major determining factor in release. As such, following intravenous injection HPPH would be less likely to be bound by BSA when delivered as AuNC-HPPH than free HPPH. Additionally, because of its accumulation in tumors, 14 AuNC-HPPH would likely deliver a larger HPPH dose to the cell membrane itself. The release could be further controlled with PT heating by the AuNCs (Fig. 6) . Under NIR irradiation by a diode laser (1 W/cm 2 at 808 nm) that overlaps with the LSPR, the solution temperature was held at 46 o C for 2 h. 49, 50 In the dark, only 26.2 ± 6.7 % of the payload was 15 released from the PEG layer after two hours. The slow release profile should provide enough time for the AuNC-HPPH to accumulate in the tumor prior to unloading, as demonstrated in our previous in vivo study. 14 Irradiation led to localized heating, which presumably increased the fluidity of the PEG/HPPH layer, enabling HPPH to rapidly diffuse to the interface and interact with BSA. We speculate that this change might be the result of disruption of the hydration of the PEG 51 and/or partial collapse of the PEG layer, 52 increasing molecular motion due to thermal energy. A linear burst release (69.2 ± 5.0 %) in the first 45 min was observed, after which the release proceeded gradually, only reaching ~75 % when the study terminated after two hours.
The residual HPPH is unlikely to be trapped within the nanocage void because the loading capacity of AuNCs by diffusion to their interiors was ~100 HPPHs/AuNC (Fig. S3) , which accounted for only 0.1 % of the total loaded HPPH. Thus, the remaining HPPH may have been buried too deeply within the PEG layer to have interacted with BSA for release. A finer measure of control was achieved using brief pulses of irradiation, and little release was observed during the dark time. The controlled release profiles are shown in Figure 7A , and the change in temperature of equimolar AuNCs in PBS is shown in Figure 7B . The suspension temperature rose from 37 C to 46 C during the 5 min irradiation period and returned to 37 C during the 10 min dark time. AuNC COO -HPPH and AuNC-HPPH were separately incubated in BSA for 5 min prior to the first irradiation. During the first laser pulse roughly 20 and 30 % of the respective payloads were released, and only a further 5 % released in the dark time that followed. The second pulse resulted in 15 and 20 % of the respective payloads being released, and the final pulse released ~10 % of the payload. Ultimately, ~60 % and ~80 % of the payload was released from AuNC COO -HPPH and AuNC-HPPH, respectively. Faster release was observed for AuNC-HPPH than AuNC COO -HPPH, similar to the dark release (Fig. 7A) . Both samples demonstrated similar capacity for on-demand release, though AuNC COO -HPPH seemed to be more responsive to the irradiation. The slow release observed in the absence of irradiation suggests that little premature leakage would occur during transport from the injection site to the tumor, but the extensive, controllable release of the payload suggests that extensive unloading can be accomplished quickly within the tumor. Furthermore, release was achieved using photothermally therapeutic temperatures, suggesting that photothermal unloading could provide the benefits of both PT therapy and on-demand drug delivery. 
CONCLUSION
We have systematically investigated the use of PEG-coated AuNCs as a platform to deliver a photosensitizer namely HPPH by a number of methods including fluorescence intensity and lifetimes, Raman spectroscopy, DLS, and zeta potential measurements. HPPH was found to densely pack within the PEG coating, rather than aggregating at the surface. The loading capacity could be maximized to be ~2 × 10 5 HPPHs/AuNC, which is attributable to the hydrophobic interaction between HPPH and the PEG layer with a K d of ~35 μM. Release of cargo from this delivery system was investigated in albumin-containing media to mimic in vivo delivery following intravenous injection and in vesicles to mimic unloading to the cell membrane. The release was found to be slightly faster for albumin, although the timeframes are comparable. This suggests that, in vivo, HPPH would be unloaded to both serum proteins and cell membranes. Changing the ionic character of the PEG terminus affected the release rate by modifying the interactions with dissolved proteins, and crosslinking the termini provides a steric block that prevents undesired unloading. On-demand release could be accomplished by using irradiation to induce the PT effect.
Release studies in a serum-mimetic environment and a suspension of cell membrane mimetic vesicles provide a general method to optimize drug delivery systems prior to costly in vitro and in vivo evaluation. In combination with our previous in vivo demonstration of AuNC-HPPH efficacy, 14 this work has established fundamental understanding of the PEG-covered AuNC platform in the delivery of HPPH, which may help elucidate the fate of other non-covalent drugpolymer systems in vivo. The PEG-covered AuNC system integrated with stimuli-responsive cross-linkers can potentially serve as a multifunctional platform for controlled delivery of a wide variety of hydrophobic drugs. Further utilizing the optical properties of AuNC, 50 these systems can achieve theranostics through diagnosis via AuNC contrast-enhanced molecular imaging and multi-modal treatment via photodynamic-, photothermal-, and chemo-therapies.
